Roche has teamed up with researchers in Australia to study the immune and biological mechanisms leading to better outcomes…
Articles by Patricia Inacio, PhD
About 10%-20% of people with multiple sclerosis (MS) receive baclofen to control their spasticity, but up to…
Celiac disease, in which the ingestion of gluten causes the immune system to attack the lining of the small intestine,…
Frequency Therapeutics has established a clinical advisory board, with experts across neuroscience fields, to help guide its small…
The severity of sexual dysfunction doesn’t seem to be associated with MRI measures of disease activity in multiple sclerosis…
The U.S. Patent and Trademark Office will grant Trethera Corp. a new patent covering the composition and chemical structure…
The presence of self-reactive antibodies, typically seen in autoimmune diseases like scleroderma, may be common among patients with…
People with high levels of free vitamin D in circulation before the age of 20 have a lower risk of…
While sexual problems are relatively common in women with multiple sclerosis (MS), it can still be difficult to…
NervGen Pharma has been cleared to enroll a second group of healthy volunteers into the multiple ascending dose portion…
Multiple sclerosis (MS) treatments belonging to the class of sphingosine 1-phosphate (S1P) receptor modulators — such as…
A researcher at the University of Adelaide, in Australia, has received an AU$390,000 grant (about $280,000) to investigate how inflammatory…
A neurology professor at the University of Pennsylvania (UPenn) has received the 2021 Barancik Prize for Innovation in MS…
Atara Biotherapeutics has partnered with Imeka to use its proprietary biomarker imaging technology in the ongoing EMBOLD Phase…
Adults with multiple sclerosis (MS) and depression or anxiety, especially those of minority groups, are being asked to join…
NervGen Pharma has received approval to begin testing multiple ascending doses of NVG-291, its lead therapeutic candidate for…
XRHealth, a virtual reality clinic that provides treatments in patients’ homes, has integrated Tobii‘s eye-tracking technology into its…
Women with multiple sclerosis (MS) who receive high-efficacy disease-modifying therapies (DMTs) before conception have a greater risk of…
The U.S. Food and Drug Administration (FDA) has approved Lyvispah, a dissolvable granular formulation of baclofen, to treat…
Lucid-MS, a new chemical molecule being developed by FSD Pharma for the treatment of multiple sclerosis (MS), has…
A researcher at the University of Houston has received a $100,000 grant to investigate adherence to oral disease-modifying therapies (DMTs)…
A new collaboration between Arterys and Combinostics seeks to bring comprehensive artificial intelligence (AI) imaging solutions to the…
The Multiple Sclerosis Society of Canada is urging that all provinces and territories in Canada offer COVID-19Â booster vaccines to…
The number of lesions affecting the cerebellum — a brain region responsible for coordinating voluntary movements and motor skills such…
Sanofi Genzyme has extended its collaboration with Koneksa to bring digital measures into its Phase 3 trials…
The Scottish Medicines Consortium (SMC) has recommended that Ponvory (ponesimod) be offered through the National Health Service (NHS) Scotland to people with active,…
Numares has signed an exclusive licensing agreement with Oxford University Innovation to develop and commercialize a panel of…
New preclinical data continues to support the potential of Cyxone’s investigational plant-derived peptide T20K for the treatment of…
The U.S. Patent and Trademark Office will grant Medsenic a patent covering the use of Arscimed, its investigational formulation…
Innodem Neurosciences is teaming up with Novartis Canada on a breakthrough clinical trial to evaluate if Innodem’s digital…